|Bid||170.01 x 1100|
|Ask||170.04 x 800|
|Day's range||169.96 - 171.24|
|52-week range||155.72 - 186.69|
|Beta (5Y monthly)||0.59|
|PE ratio (TTM)||24.77|
|Forward dividend & yield||4.52 (2.66%)|
|Ex-dividend date||22 Aug 2022|
|1y target est||N/A|
NEW BRUNSWICK, N.J., August 09, 2022--Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th, at the Sheraton New York Hotel in New York. Joaquin Duato, Chief Executive Officer, and Joseph J. Wolk, Executive Vice President and Chief Financial Officer will represent the Company in a session scheduled at 11:10 a.m. (Eastern Time).
NEW BRUNSWICK, N.J., August 08, 2022--Johnson & Johnson (NYSE: JNJ) ("the Company") announced today that Mathai Mammen, M.D., Ph.D., has decided to leave his position as Executive Vice President, Pharmaceuticals, R&D, and pursue other opportunities outside of the Company. William Hait, M.D., Ph.D., will serve as interim head of the Pharmaceutical R&D organization until new leadership is identified.
NEW BRUNSWICK, N.J., August 02, 2022--Johnson & Johnson (NYSE: JNJ) will participate in the 2022 Wells Fargo Securities Healthcare Conference at the Encore Boston Harbor in Everett, MA on Wednesday, September 7th. Ashley McEvoy, Executive Vice President, Worldwide Chairman, MedTech will represent the Company in a session scheduled at 11:00 a.m. (Eastern Time).